STRATTERA 100mg capsules medication leaflet

N06BA09 atomoxetine • Nervous system | Psychostimulants, agents used for adhd and nootropics | Centrally acting sympathomimetics

Atomoxetine is a selective norepinephrine reuptake inhibitor (sNRI) medication used to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, cognitive disengagement syndrome (CDS).
It may be used alone or along with stimulant medication.
It enhances the executive functions of self-motivation, sustained attention, inhibition, working memory, reaction time, and emotional self-regulation.
Use of atomoxetine is only recommended for those who are at least six years old.
It is taken orally. The effectiveness of atomoxetine is comparable to the commonly prescribed stimulant medication methylphenidate.

Atomoxetine alleviates ADHD symptoms through norepinephrine reuptake inhibition and by indirectly increasing dopamine in the prefrontal cortex, sharing 70-80% of the brain regions with stimulants in their produced effects.

Unlike α2-adrenergic receptor agonists such as guanfacine and clonidine, atomoxetine's use can be abruptly stopped without significant withdrawal symptoms being observed.

General data about STRATTERA 100mg

Substance: atomoxetine

Date of last drug list: 19-03-2019

Commercial code: W65187004

Concentration: 100mg

Pharmaceutical form: capsules

Quantity: 56

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: LILLY S.A. - MAREA BRITANIE

Holder: ELI LILLY NEDERLAND B.V. - OLANDA

Number: 8951/2016/04

Shelf life: 3 years

Pharmaceutical forms available for atomoxetine

Concentrations available for atomoxetine

100mg, 10mg, 18mg, 25mg, 40mg, 4mg/ml, 60mg, 80mg

Other substances similar to atomoxetine